Mesalazin Orion (Mesalazine)

Mesalazine works by inhibiting cyclooxygenase and lipoxygenase enzymes, which lowers prostaglandin and leukotriene production. It also modulates nuclear factor‑κB signaling and scavenges free radicals, resulting in decreased cytokine release and attenuation of mucosal inflammation in the gastrointestinal tract.

The specific dose of Mesalazin Orion is individualized by the prescribing clinician based on disease severity, location, and patient factors. Dosage regimens are not standardized in public information and should be followed exactly as directed by a qualified healthcare professional.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity, and submit the request. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

Mesalazin Orion belongs to the aminosalicylate class, offering a topical anti‑inflammatory effect within the gut. Compared with sulfasalazine, it lacks the sulfapyridine moiety, resulting in fewer systemic side effects. Biologic agents provide deeper immunomodulation but are typically reserved for moderate‑to‑severe disease unresponsive to aminosalicylates.

Store Mesalazin Orion at temperatures below 25 °C in its original container, protecting it from moisture and direct sunlight. Do not expose the product to excessive heat or humidity, and keep it out of reach of children.

Mesalazin Orion is taken orally, usually with a full glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Swallow tablets whole; do not crush or chew unless specifically instructed by a healthcare provider.

Serious adverse events, although rare, include myocarditis or pericarditis, severe liver injury, blood dyscrasias such as neutropenia or thrombocytopenia, Stevens‑Johnson syndrome, and pancreatitis. Patients should seek immediate medical attention if they experience chest pain, jaundice, unexplained fever, severe skin reactions, or abdominal pain.

Mesalazin Orion is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the formulation. Patients with severe renal or hepatic impairment, active cardiac inflammation, or a history of severe allergic reactions to aminosalicylates should avoid its use unless directed by a specialist.